Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Repare Therapeutics Inc. (RPTX) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Repare Therapeutics Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1808158.
Total stock buying since 2020: $110,934,875.
Total stock sales since 2020: $92,902,805.
Total stock option exercises since 2020: $546,393.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 37,270 | $42,486 | 0 | $0 |
| 2024 | 0 | $0 | 21,690 | $101,058 | 0 | $0 |
| 2023 | 783,709 | $2,821,352 | 10,473 | $125,972 | 0 | $0 |
| 2022 | 3,404,080 | $41,398,923 | 2,250,533 | $27,573,022 | 48,507 | $108,849 |
| 2021 | 7,500 | $210,600 | 1,952,293 | $59,979,015 | 94,552 | $198,177 |
| 2020 | 3,325,200 | $66,504,000 | 150,000 | $5,081,252 | 115,304 | $239,367 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-03 | 0 | $0 | 37,270 | $42,486 | 0 | $0 |
| 2024-04 | 0 | $0 | 3,990 | $18,478 | 0 | $0 |
| 2024-03 | 0 | $0 | 17,700 | $82,580 | 0 | $0 |
| 2023-11 | 783,709 | $2,821,352 | 0 | $0 | 0 | $0 |
| 2023-06 | 0 | $0 | 10,473 | $125,972 | 0 | $0 |
| 2022-12 | 0 | $0 | 0 | $0 | 48,507 | $108,849 |
| 2022-06 | 1,986,119 | $23,757,673 | 2,250,000 | $27,567,000 | 0 | $0 |
| 2022-05 | 420,000 | $3,570,000 | 0 | $0 | 0 | $0 |
| 2022-03 | 0 | $0 | 533 | $6,022 | 0 | $0 |
| 2022-01 | 997,961 | $14,071,250 | 0 | $0 | 0 | $0 |
| 2021-12 | 0 | $0 | 0 | $0 | 48,511 | $108,858 |
| 2021-11 | 7,500 | $210,600 | 20,000 | $550,700 | 46,041 | $89,319 |
| 2021-09 | 0 | $0 | 74,952 | $2,555,604 | 0 | $0 |
| 2021-08 | 0 | $0 | 185,832 | $6,337,406 | 0 | $0 |
| 2021-07 | 0 | $0 | 89,430 | $3,021,740 | 0 | $0 |
| 2021-06 | 0 | $0 | 259,687 | $8,734,684 | 0 | $0 |
| 2021-05 | 0 | $0 | 245,468 | $8,393,516 | 0 | $0 |
| 2021-04 | 0 | $0 | 5,512 | $192,975 | 0 | $0 |
| 2021-03 | 0 | $0 | 1,071,412 | $30,192,390 | 0 | $0 |
| 2020-12 | 0 | $0 | 150,000 | $5,081,252 | 115,304 | $239,367 |
| 2020-06 | 3,325,200 | $66,504,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-12 | Forte Steve (EVP, CHIEF FINANCIAL OFFICER) | Sale | 6,884 | 1.14 | 7,847 |
| 2025-03-12 | Koehler Maria (EVP, CHIEF MEDICAL OFFICER) | Sale | 3,596 | 1.14 | 4,099 |
| 2025-03-12 | Zinda Michael (EVP, CHIEF SCIENTIFIC OFFICER) | Sale | 5,611 | 1.14 | 6,396 |
| 2025-03-12 | Segal Lloyd Mitchell (PRESIDENT AND CEO) | Sale | 21,179 | 1.14 | 24,144 |
| 2024-04-01 | Forte Steve (EVP, CHIEF FINANCIAL OFFICER) | Sale | 789 | 4.61 | 3,637 |
| 2024-04-01 | Koehler Maria (EVP, CHIEF MEDICAL OFFICER) | Sale | 300 | 4.66 | 1,398 |
| 2024-04-01 | Zinda Michael (EVP, CHIEF SCIENTIFIC OFFICER) | Sale | 410 | 4.66 | 1,910 |
| 2024-04-01 | Segal Lloyd Mitchell (PRESIDENT AND CEO) | Sale | 2,491 | 4.63 | 11,533 |
| 2024-03-28 | Forte Steve (EVP, CHIEF FINANCIAL OFFICER) | Sale | 825 | 4.62 | 3,811 |
| 2024-03-28 | Koehler Maria (EVP, CHIEF MEDICAL OFFICER) | Sale | 500 | 4.64 | 2,320 |
| 2024-03-28 | Zinda Michael (EVP, CHIEF SCIENTIFIC OFFICER) | Sale | 450 | 4.64 | 2,088 |
| 2024-03-28 | Segal Lloyd Mitchell (PRESIDENT AND CEO) | Sale | 2,650 | 4.62 | 12,243 |
| 2024-03-27 | Forte Steve (EVP, CHIEF FINANCIAL OFFICER) | Sale | 825 | 4.62 | 3,811 |
| 2024-03-27 | Koehler Maria (EVP, CHIEF MEDICAL OFFICER) | Sale | 500 | 4.62 | 2,310 |
| 2024-03-27 | Zinda Michael (EVP, CHIEF SCIENTIFIC OFFICER) | Sale | 450 | 4.62 | 2,079 |
| 2024-03-27 | Segal Lloyd Mitchell (PRESIDENT AND CEO) | Sale | 2,650 | 4.63 | 12,269 |
| 2024-03-26 | Forte Steve (EVP, CHIEF FINANCIAL OFFICER) | Sale | 825 | 4.60 | 3,794 |
| 2024-03-26 | Koehler Maria (EVP, CHIEF MEDICAL OFFICER) | Sale | 500 | 4.60 | 2,300 |
| 2024-03-26 | Zinda Michael (EVP, CHIEF SCIENTIFIC OFFICER) | Sale | 450 | 4.61 | 2,074 |
| 2024-03-26 | Segal Lloyd Mitchell (PRESIDENT AND CEO) | Sale | 2,650 | 4.64 | 12,296 |
| 2024-03-25 | Forte Steve (EVP, CHIEF FINANCIAL OFFICER) | Sale | 825 | 4.79 | 3,951 |
| 2024-03-25 | Koehler Maria (EVP, CHIEF MEDICAL OFFICER) | Sale | 500 | 4.78 | 2,390 |
| 2024-03-25 | Zinda Michael (EVP, CHIEF SCIENTIFIC OFFICER) | Sale | 450 | 4.78 | 2,151 |
| 2024-03-25 | Segal Lloyd Mitchell (PRESIDENT AND CEO) | Sale | 2,650 | 4.79 | 12,693 |
| 2023-11-02 | Lampert Mark N | Buy | 783,709 | 3.60 | 2,821,352 |
| 2023-06-08 | Zinda Michael (EVP, Chief Scientific Officer) | Sale | 2,869 | 12.02 | 34,485 |
| 2023-06-07 | Zinda Michael (EVP, Chief Scientific Officer) | Sale | 6,404 | 12.03 | 77,040 |
| 2023-06-06 | Zinda Michael (EVP, Chief Scientific Officer) | Sale | 1,200 | 12.04 | 14,447 |
| 2022-12-20 | Koehler Maria (EVP, Chief Medical Officer) | Option Ex | 48,507 | 2.24 | 108,849 |
| 2022-06-13 | Lampert Mark N | Buy | 149,161 | 12.73 | 1,898,819 |
| 2022-06-06 | Lampert Mark N | Buy | 6,869 | 13.21 | 90,753 |
| 2022-06-03 | Versant Vantage I Gp-gp, Llc (10% Owner) | Sale | 750,000 | 12.25 | 9,189,000 |
| 2022-06-03 | Jerel Davis (Director) | Sale | 750,000 | 12.25 | 9,189,000 |
| 2022-06-03 | Versant Ventures V (canada), L.p. (10% Owner) | Sale | 750,000 | 12.25 | 9,189,000 |
| 2022-06-03 | Lampert Mark N | Buy | 644,044 | 12.29 | 7,912,724 |
| 2022-06-02 | Lampert Mark N | Buy | 1,186,045 | 11.68 | 13,855,377 |
| 2022-05-18 | Lampert Mark N | Buy | 420,000 | 8.50 | 3,570,000 |
| 2022-03-15 | Zinda Michael (EVP, Chief Science Officer) | Sale | 533 | 11.30 | 6,022 |
| 2022-01-19 | Lampert Mark N | Buy | 997,961 | 14.10 | 14,071,250 |
| 2021-12-10 | Koehler Maria (EVP, Chief Medical Officer) | Option Ex | 48,511 | 2.24 | 108,858 |
| 2021-11-23 | Zinda Michael (EVP, Chief Science Officer) | Option Ex | 46,041 | 1.94 | 89,319 |
| 2021-11-16 | Civik Thomas (Director) | Buy | 7,500 | 28.08 | 210,600 |
| 2021-11-15 | Zinda Michael (EVP, Chief Science Officer) | Sale | 20,000 | 27.54 | 550,700 |
| 2021-09-07 | Bonita David P | Sale | 887 | 33.93 | 30,095 |
| 2021-09-07 | Orbimed Capital Llc | Sale | 887 | 33.93 | 30,095 |
| 2021-09-03 | Bonita David P | Sale | 7,197 | 34.00 | 244,698 |
| 2021-09-03 | Orbimed Capital Llc | Sale | 7,197 | 34.00 | 244,698 |
| 2021-09-02 | Bonita David P | Sale | 16,424 | 34.24 | 562,357 |
| 2021-09-02 | Orbimed Capital Llc | Sale | 16,424 | 34.24 | 562,357 |
| 2021-09-01 | Bonita David P | Sale | 12,968 | 33.98 | 440,652 |
| 2021-09-01 | Orbimed Capital Llc | Sale | 12,968 | 33.98 | 440,652 |
| 2021-08-31 | Bonita David P | Sale | 8,472 | 33.94 | 287,539 |
| 2021-08-31 | Orbimed Capital Llc | Sale | 8,472 | 33.94 | 287,539 |
| 2021-08-30 | Bonita David P | Sale | 6,697 | 33.92 | 227,162 |
| 2021-08-30 | Orbimed Capital Llc | Sale | 6,697 | 33.92 | 227,162 |
| 2021-08-27 | Bonita David P | Sale | 7,093 | 33.94 | 240,736 |
| 2021-08-27 | Orbimed Capital Llc | Sale | 7,093 | 33.94 | 240,736 |
| 2021-08-26 | Bonita David P | Sale | 4,283 | 34.52 | 147,849 |
| 2021-08-26 | Orbimed Capital Llc | Sale | 4,283 | 34.52 | 147,849 |
| 2021-08-25 | Bonita David P | Sale | 7,082 | 34.34 | 243,195 |
| 2021-08-25 | Orbimed Capital Llc | Sale | 7,082 | 34.34 | 243,195 |
| 2021-08-24 | Bonita David P | Sale | 4,039 | 34.07 | 137,608 |
| 2021-08-24 | Orbimed Capital Llc | Sale | 4,039 | 34.07 | 137,608 |
| 2021-08-23 | Bonita David P | Sale | 7,094 | 34.06 | 241,621 |
| 2021-08-23 | Orbimed Capital Llc | Sale | 7,094 | 34.06 | 241,621 |
| 2021-08-18 | Bonita David P | Sale | 5,860 | 33.99 | 199,180 |
| 2021-08-18 | Orbimed Capital Llc | Sale | 2,930 | 33.99 | 99,590 |
| 2021-08-17 | Bonita David P | Sale | 34,796 | 34.12 | 1,187,238 |
| 2021-08-17 | Orbimed Capital Llc | Sale | 17,398 | 34.12 | 593,619 |
| 2021-08-16 | Zinda Michael (EVP, Chief Science Officer) | Sale | 15,000 | 34.21 | 513,150 |
| 2021-07-12 | Foley Todd (Director) | Sale | 25,559 | 33.84 | 864,916 |
| 2021-07-12 | Gadicke Ansbert (10% Owner) | Sale | 58,012 | 33.84 | 1,963,126 |
| 2021-07-09 | Foley Todd (Director) | Sale | 1,792 | 33.06 | 59,243 |
| 2021-07-09 | Gadicke Ansbert (10% Owner) | Sale | 4,067 | 33.06 | 134,455 |
| 2021-06-23 | Foley Todd (Director) | Sale | 622 | 32.98 | 20,513 |
| 2021-06-23 | Gadicke Ansbert (10% Owner) | Sale | 1,410 | 32.98 | 46,501 |
| 2021-06-22 | Foley Todd (Director) | Sale | 1,675 | 33.73 | 56,489 |
| 2021-06-22 | Gadicke Ansbert (10% Owner) | Sale | 3,800 | 33.73 | 128,155 |
| 2021-06-21 | Foley Todd (Director) | Sale | 16,562 | 34.22 | 566,668 |
| 2021-06-21 | Gadicke Ansbert (10% Owner) | Sale | 37,588 | 34.22 | 1,286,073 |
| 2021-06-18 | Foley Todd (Director) | Sale | 3,966 | 33.74 | 133,832 |
| 2021-06-18 | Gadicke Ansbert (10% Owner) | Sale | 9,000 | 33.74 | 303,705 |
| 2021-06-17 | Foley Todd (Director) | Sale | 14,328 | 33.95 | 486,435 |
| 2021-06-17 | Gadicke Ansbert (10% Owner) | Sale | 32,518 | 33.95 | 1,103,986 |
| 2021-06-16 | Foley Todd (Director) | Sale | 1,862 | 33.33 | 62,060 |
| 2021-06-14 | Foley Todd (Director) | Sale | 881 | 33.09 | 29,152 |
| 2021-06-09 | Foley Todd (Director) | Sale | 15,523 | 34.60 | 537,173 |
| 2021-06-09 | Gadicke Ansbert (10% Owner) | Sale | 35,230 | 34.60 | 1,219,134 |
| 2021-06-08 | Foley Todd (Director) | Sale | 11,544 | 33.10 | 382,164 |
| 2021-06-08 | Gadicke Ansbert (10% Owner) | Sale | 26,200 | 33.10 | 867,350 |
| 2021-06-07 | Foley Todd (Director) | Sale | 10,186 | 31.98 | 325,778 |
| 2021-06-04 | Foley Todd (Director) | Sale | 5,612 | 31.04 | 174,196 |
| 2021-06-03 | Foley Todd (Director) | Sale | 9,824 | 31.92 | 313,582 |
| 2021-06-02 | Gadicke Ansbert (10% Owner) | Sale | 6,215 | 32.12 | 199,656 |
| 2021-06-01 | Gadicke Ansbert (10% Owner) | Sale | 15,141 | 32.50 | 492,082 |
| 2021-05-28 | Gadicke Ansbert (10% Owner) | Sale | 16,742 | 32.67 | 546,961 |
| 2021-05-27 | Foley Todd (Director) | Sale | 3,503 | 32.98 | 115,546 |
| 2021-05-27 | Gadicke Ansbert (10% Owner) | Sale | 7,951 | 32.98 | 262,263 |
| 2021-05-26 | Foley Todd (Director) | Sale | 10,590 | 32.88 | 348,146 |
| 2021-05-26 | Gadicke Ansbert (10% Owner) | Sale | 24,036 | 32.88 | 790,183 |
| 2021-05-25 | Foley Todd (Director) | Sale | 2,896 | 33.23 | 96,234 |
| 2021-05-25 | Gadicke Ansbert (10% Owner) | Sale | 6,572 | 33.23 | 218,387 |
| 2021-05-24 | Foley Todd (Director) | Sale | 9,782 | 33.79 | 330,533 |
| 2021-05-21 | Foley Todd (Director) | Sale | 133,359 | 34.80 | 4,640,893 |
| 2021-05-20 | Segal Lloyd Mitchell (President and CEO) | Sale | 3,770 | 35.03 | 132,066 |
| 2021-05-20 | Foley Todd (Director) | Sale | 4,387 | 34.92 | 153,215 |
| 2021-05-19 | Segal Lloyd Mitchell (President and CEO) | Sale | 3,800 | 35.06 | 133,228 |
| 2021-05-19 | Foley Todd (Director) | Sale | 5,968 | 34.62 | 206,582 |
| 2021-05-18 | Segal Lloyd Mitchell (President and CEO) | Sale | 1,800 | 35.00 | 63,000 |
| 2021-05-18 | Foley Todd (Director) | Sale | 10,312 | 34.55 | 356,279 |
| 2021-04-15 | Segal Lloyd Mitchell (President and CEO) | Sale | 5,512 | 35.01 | 192,975 |
| 2021-03-12 | Foley Todd (Director) | Sale | 376,412 | 28.18 | 10,607,290 |
| 2021-03-12 | Gadicke Ansbert (10% Owner) | Sale | 695,000 | 28.18 | 19,585,100 |
| 2020-12-29 | Zinda Michael (EVP, Chief Science Officer) | Sale | 19,696 | 34.31 | 675,828 |
| 2020-12-28 | Zinda Michael (EVP, Chief Science Officer) | Sale | 15,048 | 34.42 | 517,952 |
| 2020-12-28 | Zinda Michael (EVP, Chief Science Officer) | Option Ex | 48 | 2.06 | 98 |
| 2020-12-24 | Zinda Michael (EVP, Chief Science Officer) | Sale | 432 | 33.14 | 14,316 |
| 2020-12-24 | Zinda Michael (EVP, Chief Science Officer) | Option Ex | 432 | 2.06 | 890 |
| 2020-12-23 | Zinda Michael (EVP, Chief Science Officer) | Sale | 16,235 | 33.87 | 549,879 |
| 2020-12-23 | Zinda Michael (EVP, Chief Science Officer) | Option Ex | 16,235 | 2.04 | 33,135 |
| 2020-12-22 | Zinda Michael (EVP, Chief Science Officer) | Sale | 41,312 | 33.68 | 1,391,388 |
| 2020-12-22 | Zinda Michael (EVP, Chief Science Officer) | Option Ex | 41,312 | 1.85 | 76,427 |
| 2020-12-21 | Zinda Michael (EVP, Chief Science Officer) | Sale | 40,000 | 33.08 | 1,323,200 |
| 2020-12-21 | Zinda Michael (EVP, Chief Science Officer) | Option Ex | 40,000 | 2.42 | 97,000 |
| 2020-12-18 | Zinda Michael (EVP, Chief Science Officer) | Sale | 8,321 | 34.84 | 289,945 |
| 2020-12-18 | Zinda Michael (EVP, Chief Science Officer) | Option Ex | 8,321 | 2.06 | 17,157 |
| 2020-12-16 | Zinda Michael (EVP, Chief Science Officer) | Sale | 8,956 | 35.59 | 318,744 |
| 2020-12-16 | Zinda Michael (EVP, Chief Science Officer) | Option Ex | 8,956 | 1.64 | 14,660 |
| 2020-06-23 | Forte Steve (EVP, Chief Financial Officer) | Buy | 5,000 | 20.00 | 100,000 |
| 2020-06-23 | Versant Vantage I Gp-gp, Llc (10% Owner) | Buy | 250,000 | 20.00 | 5,000,000 |
| 2020-06-23 | Jerel Davis (Director) | Buy | 250,000 | 20.00 | 5,000,000 |
| 2020-06-23 | Versant Ventures V (canada), L.p. (10% Owner) | Buy | 250,000 | 20.00 | 5,000,000 |
| 2020-06-23 | Morrison Briggs (Director) | Buy | 4,800 | 20.00 | 96,000 |
| 2020-06-23 | Bonita David P (Director) | Buy | 774,200 | 20.00 | 15,484,000 |
| 2020-06-23 | Segal Lloyd Mitchell (President and CEO) | Buy | 5,000 | 20.00 | 100,000 |
| 2020-06-23 | Foley Todd (Director) | Buy | 250,000 | 20.00 | 5,000,000 |
| 2020-06-23 | Schafer Carol (Director) | Buy | 8,000 | 20.00 | 160,000 |
| 2020-06-23 | Rhoads Ann D (Director) | Buy | 4,000 | 20.00 | 80,000 |
| 2020-06-23 | Orbimed Capital Llc (Director) | Buy | 774,200 | 20.00 | 15,484,000 |
| 2020-06-23 | Evnin Luke (10% Owner) | Buy | 250,000 | 20.00 | 5,000,000 |
| 2020-06-23 | Gadicke Ansbert (10% Owner) | Buy | 500,000 | 20.00 | 10,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of RPTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Repare Therapeutics Inc. (symbol RPTX, CIK number 1808158) see the Securities and Exchange Commission (SEC) website.